Vital Signs buys fluid warming company:
This article was originally published in Clinica
Anaesthesia breathing systems manufacturer Vital Signs has bought blood warming technology specialist Enginivity in a deal worth $5.9m. The deal sees Totowa, New Jersey-based Vital Signs acquire the enFlow device, a fluid warming system that brings the warming element closer to the patient, reducing heat loss and post-operative infections. The enFlow device will be introduced to market in November, and provides the company with an entry into what it claims is a $40-45m domestic market. Enginivity (Lexington, Massachusetts) sold its FDA-cleared and CE-marked products to hospitals and the US government but received no revenue in 2006.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.